Otsuka has announced a new partnership with Mylan that will see the companies bring a tuberculosis therapy to low and middle-income countries.
The partners have agreed to commercialise delamanid - an Otsuka therapy marketed under the brand name Deltyba - for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in poorer countries where this disease is prevalent.
“Otsuka is allying with Mylan to commercialise Deltyba for multidrug-resistant tuberculosis in high-burden countries.“
Under the terms of the agreement, Mylan will receive an exclusive licence from Otsuka to prioritise access to Deltyba in South Africa and India, both of which are among the highest-burden countries for MDR-TB and tuberculosis/HIV co-infection.
It is planned that this will later be expanded to include additional countries, including many other high MDR-TB burden countries where Otsuka does not have a commercial presence. A technology transfer plan has also been agreed that could allow Mylan to manufacture and distribute Deltyba for these markets in the future.
Tatsuo Higuchi, president and representative director at Otsuka, said: "Given our respective experience in the field, our two companies are well-positioned to work together in the fight against MDR-TB."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical